Published in Am J Pediatr Hematol Oncol on January 01, 1982
Cooperative Study of The Clinical Course of Sickle Cell Disease | NCT00005277
Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. Blood (2009) 2.50
Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest (2007) 2.47
Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood (2006) 2.42
A network model to predict the risk of death in sickle cell disease. Blood (2007) 2.39
Hemolysis-associated priapism in sickle cell disease. Blood (2005) 1.86
Expression patterns of fetal hemoglobin in sickle cell erythrocytes are both patient- and treatment-specific during childhood. Pediatr Blood Cancer (2011) 1.69
Enuresis is a common and persistent problem among children and young adults with sickle cell anemia. Urology (2008) 1.53
Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol (2006) 1.51
Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med (2006) 1.50
Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. Am J Hematol (2010) 1.34
Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol (2011) 1.15
Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood (2005) 1.11
Understanding pain and improving management of sickle cell disease: the PiSCES study. J Natl Med Assoc (2005) 1.10
A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia. PLoS One (2012) 1.04
Ancestry of African Americans with sickle cell disease. Blood Cells Mol Dis (2011) 0.96
NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. Br J Haematol (2011) 0.96
Prediction of fetal hemoglobin in sickle cell anemia using an ensemble of genetic risk prediction models. Circ Cardiovasc Genet (2014) 0.95
Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease. J Thromb Haemost (2014) 0.94
Supporting family adaptation to presymptomatic and "untreatable" conditions in an era of expanded newborn screening. J Pediatr Psychol (2008) 0.92
BCL11A enhancer haplotypes and fetal hemoglobin in sickle cell anemia. Blood Cells Mol Dis (2015) 0.90
Genetic determinants of haemolysis in sickle cell anaemia. Br J Haematol (2013) 0.89
Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov. Clin Trials (2015) 0.89
Increased reticulocytosis during infancy is associated with increased hospitalizations in sickle cell anemia patients during the first three years of life. PLoS One (2013) 0.88
Severe sickle cell anemia is associated with increased plasma levels of TNF-R1 and VCAM-1. Am J Hematol (2011) 0.85
Sickle cell trait diagnosis: clinical and social implications. Hematology Am Soc Hematol Educ Program (2015) 0.84
Genome-wide meta-analysis of systolic blood pressure in children with sickle cell disease. PLoS One (2013) 0.81
Bayesian Polynomial Regression Models to Fit Multiple Genetic Models for Quantitative Traits. Bayesian Anal (2015) 0.80
Decades after the cooperative study: a re-examination of systemic blood pressure in sickle cell disease. Am J Hematol (2012) 0.80
Sibling history of asthma is a risk factor for pain in children with sickle cell anemia. Am J Hematol (2008) 0.79
Sickle cell disease in children. Drugs (2012) 0.78
Association between baseline fetal hemoglobin levels and incidence of severe vaso-occlusive pain episodes in children with sickle cell anemia. Pediatr Blood Cancer (2013) 0.76
Evolving locally appropriate models of care for indian sickle cell disease. Indian J Med Res (2016) 0.75
Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. Blood (2016) 0.75
The genetics of hemoglobin A2 regulation in sickle cell anemia. Am J Hematol (2014) 0.75
Genome-wide association study to identify variants associated with vaso-occlusive pain in sickle cell anemia. Blood (2017) 0.75
Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med (1994) 15.82
Pain in sickle cell disease. Rates and risk factors. N Engl J Med (1991) 9.75
The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature (1988) 2.66
Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody. J Clin Invest (1966) 2.58
Recruitment in the Cooperative Study of Sickle Cell Disease (CSSCD). Control Clin Trials (1987) 1.93
Morphologic changes in the membranes of red blood cells undergoing hemolysis. Am J Med (1966) 1.70
Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. 3. The membrane defects caused by complement lysis. J Exp Med (1966) 1.57
Paroxysmal nocturnal haemoglobinuria. Clin Haematol (1985) 1.55
Familial cold urticaria. A generalized reaction involving leukocytosis. Arch Intern Med (1969) 1.53
Total knee replacement in morbidly obese patients. Results of a prospective, matched study. J Bone Joint Surg Br (2006) 1.49
Splenectomy for primary and recurrent immune thrombocytopenic purpura (ITP). Current criteria for patient selection and results. Ann Surg (1987) 1.37
The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood (1996) 1.34
Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest (1982) 1.32
Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood (2000) 1.29
Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells. J Clin Invest (1973) 1.29
Platelet antibody in autoimmune thrombocytopenia. Br J Haematol (1975) 1.27
Variations in the red cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol (1973) 1.24
Mechanisms of immune lysis of the red cells in hereditary erythroblastic multinuclearity with a positive acidified serum test and paroxysmal nocturnal hemoglobinuria. J Clin Invest (1974) 1.24
Chlorpropamide-induced immune hemolytic anemia. N Engl J Med (1970) 1.20
Comparison of binding characteristics of factors B and H to C3b on normal and paroxysmal nocturnal hemoglobinuria erythrocytes. J Immunol (1983) 1.20
Quantitative influence of antibody and complement coating of red cells on monocyte-mediated cell lysis. J Clin Invest (1978) 1.18
Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest (1987) 1.18
Fixation of the first component of complement (C'la) by human antibodies. J Clin Invest (1969) 1.17
Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci U S A (1988) 1.14
Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood (1993) 1.13
Erythrocyte membrane inhibitor of reactive lysis: effects of phosphatidylinositol-specific phospholipase C on the isolated and cell-associated protein. Blood (1990) 1.13
Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest (1985) 1.12
Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. II. The role of complement components in the increased sensitivity of PNH red cells to immune lysis. J Clin Invest (1966) 1.11
Measurement of the third component of complement bound to red blood cells in patients with the cold agglutinin syndrome. J Clin Invest (1973) 1.10
The lysis of paroxysmal nocturnal haemoglobinuria red cells by serum and cobra factor. Br J Haematol (1972) 1.10
Characterization of the IgG-Fc receptor on human platelets. Blood (1982) 1.09
Immune thrombocytopenia in lymphoproliferative diseases. Blood (1979) 1.08
The variability of hemolysis in the cold agglutinin syndrome. Blood (1980) 1.08
Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. J Exp Med (1988) 1.07
Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. J Clin Invest (1989) 1.07
Abnormality of glycophorin-alpha on paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest (1984) 1.07
Mechanism of complement-mediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets. J Clin Invest (1977) 1.07
Reaction of cold agglutinins with I antigen solubilized from human red cells. Blood (1970) 1.06
The population of cells in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis: significance and mechanism of increased immune lysis. Br J Haematol (1974) 1.05
Further evidence for location of the spherocytosis gene on chromosome 8. Ann Intern Med (1983) 1.04
Two populations of granulocytes in paroxysmal nocturnal hemoglobinuria. Blood (1979) 1.03
The acetylcholinesterase defect in paroxysmal nocturnal hemoglobinuria: evidence that the enzyme is absent from the cell membrane. Blood (1985) 1.01
The use of in vitro technics to study drug-induced pancytopenia. N Engl J Med (1979) 1.01
The structure of the urokinase-type plasminogen activator receptor gene. Blood (1994) 0.99
Production of IgM hexamers by normal and autoimmune B cells: implications for the physiologic role of hexameric IgM. J Immunol (1998) 0.99
Mutations within the Piga gene in patients with paroxysmal nocturnal hemoglobinuria. Blood (1994) 0.99
Fragment D-dimer levels: an objective marker of vaso-occlusive crisis and other complications of sickle cell disease. Blood (1986) 0.98
The response of human neutrophils to a chemotactic tripeptide (N-formyl-methionyl-leucyl-phenylalanine) studied by microcinematography. Blood (1984) 0.97
Cold-reacting antibodies: differences in the reaction of anti-I antibodies with adult and cord red blood cells. Blood (1970) 0.97
Separation of the acetylcholinesterase-deficient red cells in paroxysmal nocturnal hemoglobinuria. Blood (1986) 0.96
Cold-reacting antibodies: the enhancement of antibody fixation by the first component of complement (C'1a). J Immunol (1968) 0.96
Erythrocyte acetylcholinesterase deficiency in paroxysmal nocturnal hemoglobinuria (PNH). A comparison of the complement-sensitive and insensitive populations. Blood (1969) 0.95
The spleen as a filter. N Engl J Med (1987) 0.94
Quantitative immunology of immune hemolytic anemia. I. The fixation of C1 by autoimmune antibody and heterologous anti-IgG antibody. J Clin Invest (1971) 0.94
Structure-function relationships of the complement regulatory protein, CD59. Blood Cells Mol Dis (1996) 0.94
Structure of the CD59-encoding gene: further evidence of a relationship to murine lymphocyte antigen Ly-6 protein. Proc Natl Acad Sci U S A (1992) 0.94
The life-span of complement-sensitive and -insensitive red cells in paroxysmal nocturnal hemoglobinuria. Blood (1971) 0.94
Differences in the terminal steps of complement lysis of normal and paroxysmal nocturnal hemoglobinuria red cells. Blood (1978) 0.94
Paroxysmal nocturnal haemoglobinuria in aplastic anaemia. Clin Haematol (1978) 0.94
Inhibitors of complement derived from the erythrocyte membrane in paroxysmal nocturnal hemoglobinuria. Blood (1980) 0.93
Platelet-bound complement (C3) in immune thrombocytopenia. Blood (1977) 0.93
Hormone receptor status in primary breast cancer--time for a consensus? Eur J Cancer (2002) 0.92
The reactivity of red blood cell membrane glycophorin with "cold-reacting" antibodies. Clin Immunol Immunopathol (1975) 0.91
The control of complement activation by the blood cells in paroxysmal nocturnal hemoglobinuria. Blood (1986) 0.91
Complement-dependent immune adherence measured with human granulocytes: changes in the antigenic nature of red cell-bound C3 produced by incubation in human serum. Clin Immunol Immunopathol (1973) 0.91
Intravenous immunoglobulin administration in the treatment of severe chronic immune thrombocytopenic purpura. Am J Med (1984) 0.90
Treatment of paroxysmal nocturnal hemoglobinuria. Blood (1982) 0.90
Pseudo-Bernard-Soulier syndrome: thrombocytopenia caused by autoantibody to platelet glycoprotein Ib. Blood (1987) 0.89
Paroxysmal nocturnal hemoglobinuria--present status and future prospects. West J Med (1980) 0.89
Red-cell abnormalities in HEMPAS (hereditary erythroblastic multinuclearity with a positive acidified-serum test). Br J Haematol (1972) 0.89
The PIG-A mutation and absence of glycosylphosphatidylinositol-linked proteins do not confer resistance to apoptosis in paroxysmal nocturnal hemoglobinuria. Blood (1998) 0.88
Successful treatment of hepatitis C in sickle-cell disease. Ann Intern Med (2000) 0.88
Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H. Proc Natl Acad Sci U S A (1987) 0.88
Distinct restriction of complement- and cell-mediated lysis. J Immunol (1989) 0.88
The complement sensitivity on PNH cells. Ser Haematol (1972) 0.88
Structural characteristics of hemolytic antibodies as determined by the effects of ionizing radiation. J Immunol (1967) 0.88
Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. Blood (1992) 0.88
Glycosyl-phosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria: partial or complete defect in an early step. Blood (1994) 0.87
Dr Ham's test revisited. Blood (1991) 0.86
Recurrent thrombocytopenia following idiopathic thrombocytopenic purpura. The importance of platelet-bound IgG in establishing cause. Arch Intern Med (1980) 0.86
Resolution of Budd-Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol (1996) 0.85
Pulmonary embolism and splenic infarction in a patient with sickle cell trait. Am J Hematol (1990) 0.85
Reactions of immunoglobulin G-binding ligands with platelets and platelet-associated immunoglobulin G. J Clin Invest (1984) 0.84
Factors controlling erythropoiesis in birds. Blood (1966) 0.84
Genetic instability and the etiology of somatic PIG-A mutations in paroxysmal nocturnal hemoglobinuria. Blood Cells Mol Dis (1999) 0.83
Immunophenotypic analysis of reticulocytes in paroxysmal nocturnal hemoglobinuria. Blood (1995) 0.83
Refocusing on history-taking skills during internal medicine training. Am J Med (1996) 0.82
Complement sensitivity of paroxysmal nocturnal hemoglobinuria bone marrow cells. Blood (1980) 0.82
Presence of P blood group antigens on human platelets. Am J Clin Pathol (1985) 0.82
The erythropoiesis-stimulating factors produced by tumors. Ann N Y Acad Sci (1968) 0.82
Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med (1991) 0.82
Selective chemotherapy of macrophages in the treatment of idiopathic thrombocytopenic purpura. N Engl J Med (1978) 0.81
Treatment of chronic immune thrombocytopenia. Clin Haematol (1983) 0.81
Potassium permeability in -thalassemia minor red blood cells. J Clin Invest (1972) 0.81
The autinglobulin test in autoimmune hemolytic anemia. Annu Rev Med (1975) 0.81
Congential dyserythropoietic anemia--type IV. J Pediatr (1975) 0.81
The origin of ABH antigens on human platelets. Blood (1985) 0.81
The effect of iron therapy in paroxysmal nocturnal hemoglobinuria. Blood (1970) 0.81
Monocyte-mediated destruction in the presence of serum of red cells coated with antibody. Blood (1979) 0.81
Prognostic implications for direct platelet-associated IgG in childhood idiopathic thrombocytopenic purpura. Am J Pediatr Hematol Oncol (1986) 0.80